HCC in Older Patients
|
|
- Chloe Turner
- 5 years ago
- Views:
Transcription
1 Dig Dis Sci (2010) 55: DOI /s ORIGINAL ARTICLE HCC in Older Patients Brian I. Carr Petr Pancoska Robert A. Branch Received: 2 December 2009 / Accepted: 19 February 2010 / Published online: 18 March 2010 Ó Springer Science+Business Media, LLC 2010 Abstract Background Hepatocellular carcinoma (HCC) is a heterogeneous disease, with many poorly-defined prognostic patient subsets. Identification of discrete subsets will aid rational patient and treatment selection. Methods A database with 778 biopsy-proven, unresectable and untransplantable HCC patients who were followed from diagnosis till death was interrogated. Using a moving average algorithm, patients were ordered by survival and then survival cohorts were analyzed according to standard liver function and CT characteristic parameters. Results We found characteristic age clustering groupings by survival. In the older age patients, two survival sub-groups were identified, with days in one and 330 1,250 days survival in the other group. The longer surviving group had the lowest serum bilirubin and AFP levels and the lowest tumor mass. Remarkably, the trends for both AFP and bilirubin were similar, suggesting that they were not independent variables. This idea was supported by the similar correlation of typical AFP with GGTP, ALKP and SGOT levels. Conclusions A large HCC cohort showed significant age clustering characteristics for survival, especially in older patients. AFP, bilirubin and age were found to be interrelated factors for HCC severity and survival. B. I. Carr (&) Department of Medical Oncology, Liver Tumor Program, Kimmel Cancer Center, Thomas Jefferson University, Bluemle Building, Room 1002, 233 S.10th Street, Philadelphia, PA 19107, USA brian.carr@jefferson.edu P. Pancoska R. A. Branch Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, PA, USA Keywords Hepatoma AFP Survival Elderly Abbreviations HCC Hepatocellular carcinoma AFP Alpha-fetoprotein GGTP Gamma glutamyl transpeptidase ALKP Alkaline phosphatase CT Computerized axial tomography scan Introduction Meaningful analysis of clinical practice data is in general a complicated task. In this study we present a special case of clinical practice data of a large cohort of HCC patients where the unique design, together with a tailored data analysis approach, provided novel insight into the factors behind the HCC as well as tools for survival prognosis. Most hepatocellular carcinoma (HCC) arises on the basis of chronic hepatitis or cirrhosis or both. The prognosis is considered to depend on tumor factors such as serum alpha-fetoprotein (AFP) levels and tumor size, as well as liver factors such as serum bilirubin, gamma glutamyl transpeptidase (GGTP), alkaline phosphatase (ALKP) and transaminase levels. It is likely that there is even an interaction between these processes, since cirrhosis is a pre-malignant condition, leading to either liver failure, HCC or both. This dual set of influences was initially reflected in the staging system of Okuda et al. [1] and subsequently by many other systems in which greater complexity was taken into account in an effort to identify prognostic subsets for survival [2 7]. AFP is included amongst many of these HCC scoring and classification
2 Dig Dis Sci (2010) 55: systems, as its higher levels have been shown in multiple published series to represent worse prognosis [8 12]. Here we show quantitative evidence that while HCC is a heterogeneous disease, differences between its subcategories can be clearly articulated with the help of newly observed coherences between the levels of several clinical parameters. Our findings are that patients older than 55 years with non-resectable HCC can be categorized into multiple, clinically diverse, but internally homogeneous groupings. These groupings exhibit two unique and very different survival ranges, one being long ( days) and the other short (45 80 days). Methods Patients Seven hundred seventy-eight patients with unresectable and biopsy-proven HCC, who had a complete clinical dataset, were followed from diagnosis till death. They were unresectable due either to the presence of multiple and bilobar liver lesions, the presence of portal venous thrombosis or to abnormal liver function parameters and were treated with cisplatin-based chemoembolization. Therefore, no censoring was needed in the data processing. Their survival time was recorded. All patients had baseline liver function tests, including GGTP (gamma glutamyl transpeptidase) levels, AFP (alpha-fetoprotein) serum tumor marker levels and baseline helical CT (computerized axial tomography) scans performed. Analysis Strategy Our processing started from visualization of all possible correlations of survival-ordered serum parameter value pairs. This revealed that the uncertainty of the actual disease status of patients that come for treatment in random stages of the disease obscures details of the underlying data structures. We therefore used a moving average processing method [13 15] with the optimized size of the averaging window (the number of patients with the most similar survival times in one group, whose clinical parameters were averaged to characterize the mean survival of any such group). Our optimization algorithm [16] resulted in a size of 101 patients in these subcohorts. Consequently, we were able to characterize 678 survival times. Each of these central survivals was characterized by individual clinical data obtained within a 101-patient subgroup, with 50 patients having shorter survival, closest to the central survival, and 50 patients having longer survival, closest to the central one (50? 1? 50 = 101). The complete data processed in this way covered the interval of actual survivals ranging from 30 to 1,250 days. We systematically checked by standard statistical methods that the survivaldependent means for all parameters were not influenced by biases and problems caused by presence of outliers or discontinuities in the variances of the data as we moved along this survival interval. With this averaging, we lost to a certain degree the relevance of our results for an individual patient. We therefore included a final step in our analysis in which we took advantage of the fact that in all projections, all 678 subcohorts of 101 patients were identical. This allowed us to compute for each of the 101-subcohorts the exact percentages of patients with actual (i.e., non-averaged), normal and abnormal levels of all clinical serum parameters. In this way, we could have the best of both typical characterization of the disease (revealing more information about the underlying biology or pathophysiology of HCC), as well as an individual patient s characterization of the survival category in terms of probabilities of the correct prognosis (described in detail below). A multi-parameter coherence observed as significant in one or more twoparameter projections provides the tool for starting to build up the steps of a multi-parameter survival classification scheme. The significance of results for individual patients is such that we designed our filtering algorithm to preserve the exact identity of all 101 patients in all 678 characterized survivals in all pair-wise parameter projections. This allowed us to provide probabilistic characterization of clinical state for patients in every subcohort [17]. We used the 101 patients in all 678 subcohorts to estimate the probability that out of 100 individual patients of age 55 and older presenting at baseline with HCC with the actual outcome within either the 350 1,250 day survival category or the day survival category, that each will have a certain survival-category unique (and thus recognizable with confidence) combination of their clinical parameter levels. For this purpose, we first dichotomized all parameters into normal and elevated categories by coding their actual baseline parameter levels as normal (code 1) or abnormal (code 0), using the generally accepted serum parameter thresholds. These dichotomizing parameter codes that were determined from individual data for each patient in the cohort were then ordered according to patient actual survival and processed by a moving average window of ±50 patients. We then multiplied the resulting mean value of the parameter factor for every survival by 101 to recover the number N of patients with normal levels of any parameter in each 101 patient subcohort that was used to characterize survival. The number of patients with elevated levels of each parameter in each subcohort was therefore E = [101-N]. We then computed the ratio of normal to elevated patients at each subcohort R = [N/E]. This ratio
3 3586 Dig Dis Sci (2010) 55: was corrected for bias of these patient parameter levels in the whole cohort. To this effect, we determined X being % of patients with normal parameter levels and Y being % of patients with elevated parameter levels in the total cohort. Then, we computed the adjusted normal/elevated ratio AR = [Y/X] 9 R. AR[50 means that in the 101 cohort used to calculate typical values of each parameter levels for each survival, there were more patients with normal parameter levels. AR \50.0 means that there were more patients with elevated parameter levels in that subcohort. Results Age Clustering and Survival Figure 1a shows the correlation between the survival (logarithmic survival scale, re-labeled in actual survival) with typical serum total bilirubin levels. It shows that our filtering quantifies the well-described adverse prognostic effects of elevated serum bilirubin levels for survival, with higher bilirubin levels correlating with poorer survival. Our strategy in interpreting these results was to discover additional coherences in the data by overlaying the values of an additional parameter on the pair-wise correlations of typical parameters. We applied this strategy in Fig. 1 to show Fig. 1 Correlation between survival and bilirubin (a) or AFP (b) showing age clusterings that, in addition to coherence between the bilirubin and survival, there was also coherence to patient age in the subcohorts, indicated by a thick color and numbering that show two different sub-groups of patients, with typical ages above 55 years (47% of the total) showing systematic and linearly correlated increase of typical bilirubin levels with decreasing survival. These two groups are also clearly separated by the length of their survival, with days in the shorter surviving group and 330 1,250 days in the longer surviving group. Thus, if age was not an important factor for survival categorization, we would expect typical ages to be randomly distributed and not clustering without interruption, as we found. Thus, Fig. 1 indicates the importance of age as an essential part of our categorization scheme that identifies HCC subtypes. Given the prognostic importance of serum AFP levels that has been shown in many other studies, we took the same approach with serum AFP levels as we did with bilirubin (Fig. 1b). Although the AFP, in contrast to bilirubin, is considered an indicator of tumor growth, we found a very similar linear correlation in trends between serum AFP levels and survival for these two older patient groups. Interestingly, these trends between both bilirubin and AFP and survival are observably different for the subcohort of younger patients. Tumor Mass and Survival We subsequently concentrated exclusively on the older patient subgroups, because they show two completely different survival ranges, but a similar trend between survival and serum parameters. We examined the tumor burden for older patients within the long and short survival subgroups. We used the total tumor amount for this purpose, calculated as the product of the average tumor size and the total tumor number in each patient group. Figure 2a shows the relationship of total tumor burden to survival, with the longest survivors having the lowest tumor burden. The oldest patients, [80 years, were in this longest surviving subset. This estimate of total tumor mass was then plotted against typical serum AFP levels, for each survival-characteristic patient group, as shown in Fig. 2b. Because of the linear relationship between the typical AFP levels and survival (Fig. 1b), ordering of typical AFP levels on the X-axis of Fig. 2a also reflects an ordering according to survival. Thus, patients with small tumor masses and low typical AFP levels have survival on the 1,250 days end of the long-survival interval, while patients with AFP levels close to 250 and relative tumor mass of about 40 have a survival of about a year, which is the short end of the long survival interval. A similar dependence holds within the 1,000 1,000,000 ng/ml interval of AFP levels within the short (45 80 days) survival interval. We then plotted the total tumor mass against typical bilirubin levels
4 Dig Dis Sci (2010) 55: bilirubin and AFP levels follow synchronously and linearly the increase of the tumor patient tumor mass with decreasing survival (Fig. 2b). Relationships Between Tumor Factors and Liver Factors Fig. 2 Correlation of trends between tumor mass and survival (a), AFP (b) and bilirubin levels (c) for the two groupings of older patients with typical ages [55 years (Fig. 2c). This also showed a linear correlation between total tumor mass and bilirubin levels, within both the short and long survival groups, with one exception. For the subgroup of oldest patients (typically [80 years, about 10% of all patients, yellow age-color code), where the increase of the tumor mass indicates linear decrease of survival (see Figure 2), this trend is not reflected in the correlated change of bilirubin levels, which remains under the normal threshold of 1.2 mg/dl. By contrast, we showed in Fig. 2b, that for this oldest patient population, typical AFP levels increase synchronously with the increasing tumor size and decreasing survival at the longer end of the long-survival category. For the remaining patients (typical age years), both The similarity between the trends in survival for both AFP and bilirubin levels shown in Fig. 1 for the two survival groups of older patients led us to consider the possibility that tumor factors and liver factors were not completely independent, but might be somehow connected. To investigate this possibility, we plotted several serum parameters against typical AFP, including serum bilrubin, ALKP, SGOT and GGTP (Fig. 3). This identified additional coherences in the typical serum bilirubin data, shown for these two age-defined subgroups, as indicated. Again, because of the linear relationships between AFP and survival (Fig. 1), which are characteristic for this age group of patients, the ordering by AFP on the X-axis of the plots in Fig. 3 reproduces the survival ordering of patients, from the longest survival at the lowest AFP levels to the shortest survival at the highest AFP levels. This ordering is valid both globally and internally, within both survival intervals of 330 1,250 and days. Figure 3 shows a significant increase in the typical levels of all parameters between the long (330 1,250 days) and short (45 80 days) survival groups. There is a discontinuity in the AFP (=survival) versus parameter trends at the boundary between the long (left) and short (right) panels (Fig. 3). The plot shows a correlation between bilirubin and AFP values in both older age categories. The correlation is linear, with higher AFP values correlating with higher bilirubin values in each subgroup. When we overlaid patient ages onto this distinct correlation between the parameters indicating liver failure and tumor growth, the complete set of subcohorts identified in the survivalbilirubin relationship of the HCC-multidimensionality projection was transferred without exception or interruption into the bilirubin-afp projection of the HCC multidimensional characteristics consistently for both survival groups. These near identities of these different parameter relationships which we show in Figs. 1 and 3a are striking. This shows not only that bilirubin and age are coherently related to the HCC survival, but also that AFP and bilirubin with age are interrelated as factors underlying HCC severity and survival. Figure 3b d provides similar results for serum ALKP, SGOT and GGTP levels, when plotted against AFP values. These panels indicate that the coherence between all the considered serum-based parameters with age and survival is a general feature of HCC in these two older age categories, and clearly identifies the two internally homogeneous and mutually heterogeneous
5 3588 Dig Dis Sci (2010) 55: their baseline clinical characteristics that could be useful in prognosis. These are, first, the linear relationships between survival and typical levels of baseline parameters, and second, the coherence between trends between the various baseline parameters. Discussion Fig. 3 Correlation of trends of AFP to total bilirubin (a), ALKP (b), SGOT (c) and GGTP (d) levels for two groupings of HCC patients [55 years within the two survival categories subtypes of HCC that continuously combine into a resulting final HCC status that additionally reflects the better or worse survival chance within the two older age categories. This approach revealed two aspects of these patients and This study was based on an analysis of clinical practice data from 778 unresectable HCC patients presenting at a single institution, who were followed till death, without exception. This permitted use of the hard endpoint of overall survival. In order to reduce the stochasticity inherent to this type of data, we used a minimal amount of averaging to allow us to see the heterogeneity within the patient clinical parameters. We concentrated on coherences within the trends of multiple clinical parameters, so as to identify clinically relevant factors behind the HCC heterogeneity that might influence patient survival. For this approach, we started by ordering patients according to their actual survival as shown in Fig. 1. We plotted serum bilirubin and AFP levels against survival, since they are important parameters of liver failure and tumor aggressiveness, respectively. Surprisingly, the trends were remarkably similar for the distinct survival intervals, with each coherency being typical for different age groupings. The trends between survival and each parameter were simpler for the two groups of older patients [55 years, on which we subsequently focused. The two older age groups represented survival-related phenotypes of patients with days survival for ages 55 70, and 330 1,250 days for patients aged [55 years, including the oldest patients [80 years with survival of 500 1,250 days. These same age coherences were subsequently also seen when we plotted clinical parameters against each other. The trends for these two older patient categories of shorter and longer survival were then presented in one combined plot that was separated into two parts according to survival (Figs. 2 and 3). This allowed us to present their similarities and differences for each parameter under study. To better characterize the survival heterogeneity of these older patients, we examined their tumor characteristics as a function of the CT scan parameters of tumor number and size. We estimated total tumor burden as a product of baseline tumor number and median tumor size and plotted typical values against survival, serum AFP and serum bilirubin levels (Fig. 2). The shorter survival phenotype was clearly associated with the highest tumor burden. It was also associated with the highest serum AFP and bilirubin levels (Fig. 2a, b) as expected. By contrast, in the longer survival group, the serum AFP continued to be inversely proportional to survival. However, for bilirubin
6 Dig Dis Sci (2010) 55: levels, there was a difference in the trends for the longer survivors between 55 and 70 years old and [80 years old. The former displayed inverse proportionality, while the latter had a constant normal bilirubin level despite increasing tumor mass and AFP, with decreasing survival (Fig. 2c, bottom left). In order to examine why there were such similar trends in Fig. 1 for AFP and bilirubin in relation to survival, despite their representing the apparently different processes of liver damage and tumor aggressiveness, we then plotted each of the additional clinical serum parameters (ALKP, SGOT and GGTP) directly against AFP levels (Fig. 3). These plots showed two extreme types of behavior. In one, as shown in Fig. 3d, there is a linear relationship between AFP and GGTP levels that continued throughout both survival categories, without discontinuity. In the other, as shown in Fig. 3a, there are two discontinuities in the AFP and bilirubin plot. The first discontinuity occurs at AFP levels of 25 ng/ml and the second discontinuity occurs at the boundary of the longer and shorter survival groups. ALKP and SGOT plots (Fig. 3b, c) are intermediate between these two extreme patterns and do not differentiate the oldest age group in the way that the bilirubin plot does. These plots suggest to us that our simple notion of two largely independent processes of liver damage and tumor aggressiveness might need modification. This is because for each liver parameter that we plotted against AFP, our surrogate for tumor aggressiveness, we found a coherent trend between AFP levels and the liver parameter levels. This would not be expected if they were indeed independent processes. One example where these two processes are independent however, is the relationship of serum bilirubin to AFP levels in the oldest and longest surviving patients with[600 days, as depicted in Fig. 3a (extreme left end of the plot). In contrast, as serum AFP levels rise beyond 25 ng/ml, there is a linear relationship between AFP and bilirubin levels, showing their inter-dependency (rest of Fig. 3a). In this respect, bilirubin is unique, since as shown in Fig. 3b d, neither ALKP, GGTP nor SGOT levels showed the transition from independency to inter-dependency. These three parameters are thus never independent of tumor aggressiveness, as judged by AFP levels. Our dataset is unique in several aspects. First, there were no subjects who were censored or lost to follow-up. All patients were followed by a single clinician till death. Second, we have published previously an overview [18] of clinically relevant features of the raw data. For the purpose of this paper, we corrected for all un-informative biases of the data by mathematical transformations (conversion into log-transformed data, use of relative units for better comparability of parameter levels, etc.) before attempting the final data processing described in this paper. We searched for evidence for well-defined heterogeneous structure of the HCC data in this clinical study with each subtype being associated with very different survival. We characterize this heterogeneity in HCC using the combination of two complementary approaches. The first was that clinical parameter values at baseline represent a snapshot of multivariate pathophysiological factors, which operate in concert and in their unity determine the progression of the disease, quantified by multiplicities in the times to survival. In the second, we hypothesized that the projection of these complex multi-variable inter-dependencies into simpler two-parameter correlations of data, ordered systematically according to the survival of individual patients, would facilitate clear identification of the boundaries between the heterogeneous HCC subcategories. Ordering all data according to the survival before actual processing, and keeping this survival-defined order unchanged throughout the complete analysis, is an essential feature of our approach. Thus, any coherences observed for clinical parameters in the data are validating the clinical relevance of such observations, since without functional correlation between such coherently behaving parameters and the survival outcome, we can only expect random distributions of the other parameter values in the survival-ordered data vectors. References 1. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56: [No authors listed]. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28: Georgiades CS, Liapi E, Frangakis C, et al. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol. 2006;17: Kondo K, Chijiiwa K, Nagano M, et al. Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma. Hepatogastroenterology. 2007;54: Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94: Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19: Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245: Furihata T, Sawada T, Kita J, et al. Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular
7 3590 Dig Dis Sci (2010) 55: carcinoma after curative hepatectomy. Hepatogastroenterology. 2008;55(86 87): Yen YH, Changchien CS, Wang JH, et al. A modified TNMbased Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis. 2009;41(6): Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer. 1989;64(8): Dvorchik I, Carr BI. A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. Cancer Detect Prev. 2007;31(2): Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004;112(1): Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating: SBH/Statistics for Biology and Health. New York: Springer; Rizzo R, Maria L. Statistical computing. London: Chapman & Hall/CRC Press; Everitt BS, Hothorn T. A Handbook of Statistical Analyses Using R, 2nd ed. London: Chapman & Hall/CRC Press; Chaps. 5 7, Witten IH, Eibe F. Data Mining: Practical Machine Learning Tools and Techniques, 2nd ed. San Francisco: Frank Morgan Kaufmann Publishers; Chaps. 4, 6 and Maplesoft, in Statistics with Maple. Maple-edition 12. Waterloo, Ontario, Canada; Carr BI, Buch SC, Kondragunta V, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. J Gastroenterol Hepatol. 2008;23(8 Pt 1):
간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung
간암의다양한병기분류법 : 현재사용중인병기분류를중심으로 Kim, Beom Kyung Importance of staging system 환자의예후예측 적절한치료방법적용 ( 수술, 방사선, 항암..) 의료진간의 tumor burden 에대한적절한의사소통 향후연구및 clinical trial 시연구집단의성격에대한객관적기준제시 Requisites for good staging
More informationClinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan
Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan Why is staging system important? Cancer stage can be
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:989 994 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Level of -Fetoprotein Predicts Mortality Among Patients With Hepatitis C Related Hepatocellular
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationNegative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma
Li et al. World Journal of Surgical Oncology (2015) 13:294 DOI 10.1186/s12957-015-0713-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Negative impact of low body mass index on liver cirrhosis
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationAlpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer. Original Policy Date
MP 2.04.35 Alpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationIntrahepatic Sarcomatoid Cholangiocarcinoma with Portal Vein Thrombosis: A Case Report 1
Intrahepatic Sarcomatoid Cholangiocarcinoma with Portal Vein Thrombosis: A Case Report 1 Jae-Hoon Lim, M.D., Jin Woong Kim, M.D., Suk Hee Heo, M.D., Yong Yeon Jeong, M.D., Heoung Keun Kang, M.D. A 53-year-old
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationOver the past 20 years, great progress has been made in the
ORIGINAL ARTICLES Staging of Hepatocellular Carcinoma Assessment of the Japanese TNM and AJCC/UICC TNM Systems in a Cohort of 13,772 Patients in Japan Masami Minagawa, MD, PhD,* Iwao Ikai, MD, PhD,* Yutaka
More informationApplication of Artificial Neural Network-Based Survival Analysis on Two Breast Cancer Datasets
Application of Artificial Neural Network-Based Survival Analysis on Two Breast Cancer Datasets Chih-Lin Chi a, W. Nick Street b, William H. Wolberg c a Health Informatics Program, University of Iowa b
More information21/02/2014. Disclosures. HCC: predicting recurrence. Outline. Liver transplant: Beyond Milan?
Disclosures HCC: predicting recurrence Peter Ghali, MD, FRCPC, MSc (epid) None relevant to this talk other than off-label use of sirolimus Toronto, February 2014 Outline Recurrence after what? Locoregional
More informationSOMATOSTATIN RECEPTORS IN HEPATOCELLULAR CARCINOMA. Marie LEQUOY Saint-Antoine Hospital, Department of Hepatology, Paris, France
SOMATOSTATIN RECEPTORS IN HEPATOCELLULAR CARCINOMA Marie LEQUOY Saint-Antoine Hospital, Department of Hepatology, Paris, France Somatostatin : SST Somatostatin (SST) protein : 2 active forms (alternative
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationAggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases
RESEARCH ARTICLE Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases Ashraf Omar Abdel Aziz 1, Dalia Omran
More informationHepatocellular carcinoma (HCC) is the most
Original Article / Biliary Hepatobiliary & Pancreatic Diseases International Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection: a matched study Ding-Ding Wang, Li-Qun
More informationScreening for hepatocellular carcinoma (HCC) is controversial.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:508 512 Screening for Hepatocellular Carcinoma Among Veterans With Hepatitis C on Disease Stage, Treatment Received, and Survival LUCI K. LEYKUM,* HASHEM
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationStaging and prognostic systems: beyond BCLC?
Staging and prognostic systems: beyond BCLC? Alessandro Vitale, MD, PhD, FEBS U.O.C. di Chirurgia Epatobiliare e dei Trapianti Epatici, Department of Surgery, Oncology and Gastroenterology, University
More informationAddictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis
Addictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis Gwang Hyeon Choi, Ju Hyun Shim*, Min-Joo Kim, Min-Hee Ryu, Baek-Yeol
More informationTreatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories
Original Research 987 Treatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories Kuan-Ling Kuo, PhD a ; David Stenehjem, PharmD a,b ; Frederick
More informationTACE: coming of age?
Invasive procedures in the diagnosis and treatment of liver diseases: focal lesions F.Farinati Gastroenterologia, Padova TACE: coming of age? AISF 2005 TACE: LEVELS OF EVIDENCE Degree of certainty Methodology
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationTrans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?
Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:
More informationHepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010
Bronx VA Medical Center Mount Sinai School of Medicine Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Norbert Bräu, MD, MBA Associate
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationSIRTEX Lunch Symposium, Cebu, 23 Nov Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong
SIRTEX Lunch Symposium, Cebu, 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong I will not talk on Mechanism of SIRT Data on efficacy of SIRT Epidemiology
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationUnderstanding Liver Cancer: A Tale of Two Diseases
Understanding Liver Cancer: A Tale of Two Diseases Understanding Liver Cancer: A Tale of Two Diseases Brian I. Carr, MD, FRCP, PhD Director, Liver Cancer Program IRCCS de Bellis Medical Center Castellana
More informationManagement of hepatocellular carcinoma should consider both tumor factors and background liver factors
Hepatocellular Carcinoma Column: Editorial Management of hepatocellular carcinoma should consider both tumor factors and background liver factors Shuji Nomoto, Mitsuhiro Hishida, Yoshikuni Inokawa, Hiroyuki
More informationDoes the lung nodule look aggressive enough to warrant a more extensive operation?
Accepted Manuscript Does the lung nodule look aggressive enough to warrant a more extensive operation? Michael Kuan-Yew Hsin, MBChB, MA, FRCS(CTh), David Chi-Leung Lam, MD, PhD, FRCP (Edin, Glasg & Lond)
More informationHow to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung
How to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung End points in research for solid cancers Overall survival (OS) The most ideal one, but requires long follow-up duration
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationDigitizing the Proteomes From Big Tissue Biobanks
Digitizing the Proteomes From Big Tissue Biobanks Analyzing 24 Proteomes Per Day by Microflow SWATH Acquisition and Spectronaut Pulsar Analysis Jan Muntel 1, Nick Morrice 2, Roland M. Bruderer 1, Lukas
More informationPredictive Factors of Outcome and Tumor Response to Systemic Chemotherapy in Patients with Metastatic Hepatocellular Carcinoma
Predictive Factors of Outcome and Tumor Response to Systemic Chemotherapy in Patients with Metastatic Hepatocellular Carcinoma Masafumi Ikeda 1,2, Takuji Okusaka 1, Hideki Ueno 1, Chigusa Morizane 1, Yasushi
More informationPrognostic factors in patients with hepatitis B virus related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy
ONCOLOGY LETTERS 6: 1213-1218, 2013 Prognostic factors in patients with hepatitis B virus related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy HIROKI NISHIKAWA 1, NORIHIRO NISHIJIMA
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationOptimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study
Su et al. BMC Cancer (2016) 16:424 DOI 10.1186/s12885-016-2420-0 RESEARCH ARTICLE Open Access Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationOriginal Article. Comparison of 7 staging systems in north Indian cohort of hepatocellular carcinoma
Tropical Gastroenterology 2010;31(4):271 278 Original Article Comparison of 7 staging systems in north Indian cohort of hepatocellular carcinoma *Sanjay Sarma 1, *Balkrishan Sharma 1, Yogesh Kumar Chawla
More informationHow to apply HCC prediction models to practice?
How to apply HCC prediction models to practice? Department of Internal Medicine, Keimyung University School of Medicine Woo Jin Chung HCC prediction models 독특하게간세포암환자들의생존은암의진행상태뿐아니라기저간기능의중증정도에영향을받는특성이있다.
More informationTreatment of HCC in real life-chinese perspective
Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA
More informationClinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 2017;23:160-169 Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
More informationBile duct invasion can be an independent prognostic factor in early stage hepatocellular carcinoma
Korean J Hepatobiliary Pancreat Surg 2015;19:167-172 http://dx.doi.org/10.14701/kjhbps.2015.19.4.167 Original Article Bile duct invasion can be an independent prognostic factor in early stage hepatocellular
More informationGROWTH AND SURVIVAL IN SMALL HEPATOCELLULAR CARCINOMA
254 HPB INTERNATIONAL 2. Delius, R.E., Frankel, F. and Coran, A.G. (1989) A comparison between operative and nonoperative management of blunt injuries to the liver and spleen in adult and pediatric patients.
More informationNIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18.
NIH Public Access Author Manuscript Published in final edited form as: J Surg Res. 2011 April ; 166(2): 189 193. doi:10.1016/j.jss.2010.04.036. Hepatocellular Carcinoma Survival in Uninsured and Underinsured
More informationHepatocellular Carcinoma in Qatar
Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study
More informationMULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC
Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY
More informationGut Online First, published on May 5, 2005 as /gut
Gut Online First, published on May 5, 2005 as 10.1136/gut.2005.069237 p53 gene (Gendicine ) and embolization overcame recurrent hepatocellular carcinoma Guan YS, Liu Y, Zhou XP, Li X, He Q, Sun L. Authors
More informationRESEARCH ARTICLE. Di-Ya Wang 1&, Lei Liu 2&, Xing-Shun Qi 3& *, Chun-Ping Su 4, Xue Chen 3, Xu Liu 3, Jiang Chen 3, Hong-Yu Li 3, Xiao-Zhong Guo 3 *
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.13.5573 Re-Resection versus TACE for Recurrent HCC - a Meta-Analysis RESEARCH ARTICLE Hepatic Re-resection Versus Transarterial Chemoembolization for the Treatment
More informationLiver Perfusion Analysis New Frontiers in Dynamic Volume Imaging. Case Study Brochure Chang Gung Memorial Hospital.
New Frontiers in Dynamic Volume Imaging dynamic volume CT Case Study Brochure Chang Gung Memorial Hospital http://www.toshibamedicalsystems.com Toshiba Medical Systems Corporation 2010-2011. All rights
More informationInnovations in HCC Imaging: MDCT/MRI
Innovations in HCC Imaging: MDCT/MRI Anthony E. Cheng, M.D. Cardinal MRI Center Cardinal Santos Medical Center, Wilson Street, San Juan Innovations in HCC Imaging: Goals/Objectives MDCT/MRI Learn the diagnostic
More informationHepatocellular Carcinoma (HCC)
Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College
More informationWorkup of a Solid Liver Lesion
Workup of a Solid Liver Lesion Joseph B. Cofer MD FACS Chief Quality Officer Erlanger Health System Affiliate Professor of Surgery UTHSC-Chattanooga I have no financial or other relationships with any
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationINTRODUCTION. Jpn J Clin Oncol 1997;27(4)
Jpn J Clin Oncol 1997;27(4)251 257 Therapeutic Results of Resection, Transcatheter Arterial Embolization and Percutaneous Transhepatic Ethanol Injection in 3225 Patients with Hepatocellular Carcinoma:
More informationORIGINAL ARTICLE. Jun Zheng 1, Rong-chun Xing 1, Wei-hong Zheng 2, Wei Liu 1, Ru-cheng Yao 1, Xiao-song Li 1, Jian-ping Du 1, Lin Li 1.
JBUON 2017; 22(3): 709-713 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE A comparative study on postoperative mortality prediction of SFLI scoring
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationLocoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates
Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses
More informationSelective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) in the multimodal approach to Hepatocellular Carcinoma International Course on THERANOSTICS and MOLECULAR RADIOTHERAPY Brussels, 4 october 2017 Vincent Donckier
More informationSorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
Journal of the Egyptian National Cancer Institute (2014) 26, 9 13 Cairo University Journal of the Egyptian National Cancer Institute www.nci.cu.adu.eg www.sciencedirect.com Original article Sorafenib for
More informationdoi: /hepr Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)
bs_bs_banner Hepatology Research 2016; 46: 3 9 doi: 10.1111/hepr.12542 Special Report Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version) Masatoshi Kudo, Kazuomi Ueshima,
More informationRADIATION SEGMENTECTOMY. Robert J Lewandowski, MD
RADIATION SEGMENTECTOMY Robert J Lewandowski, MD Robert Lewandowski, M.D. Consultant/Advisory Board: Cook Medical, LLC, Arsenal, BTG International, Boston Scientific Corp., ABK Reference Unlabeled/Unapproved
More informationMedicine. Infiltrative Hepatocellular Carcinoma. Assessment of Factors Associated With Outcomes in Patients Undergoing Hepatectomy
Medicine OBSERVATIONAL STUDY Infiltrative Hepatocellular Carcinoma Assessment of Factors Associated With Outcomes in Patients Undergoing Hepatectomy Xiaopeng Yan, MD, Xu Fu, MD, Min Deng, MM, Jun Chen,
More informationRESEARCH ARTICLE. Hepatitis B Virus DNA Negativity Acts as a Favorable Prognostic Factor in Hepatocellular Carcinoma Patients
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.22.9635 RESEARCH ARTICLE Hepatitis B Virus DNA Negativity Acts as a Favorable Prognostic Factor in Hepatocellular Carcinoma Patients Xing Li 1&, Xiang Zhong
More informationCase Report In Situ Split of the Liver When Portal Venous Embolization Fails to Induce Hypertrophy: A Report of Two Cases
Case Reports in Surgery Volume 2013, Article ID 238675, 4 pages http://dx.doi.org/10.1155/2013/238675 Case Report In Situ Split of the Liver When Portal Venous Embolization Fails to Induce Hypertrophy:
More informationDoes CP461 Decrease Tumor Burden in HCC Patients Awaiting Liver Transplant?
Does CP461 Decrease Tumor Burden in HCC Patients Awaiting Liver Transplant? Julia H. Hayes A. Study Purpose and Rationale Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide, resulting
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed
More informationThe Egyptian Journal of Hospital Medicine (April 2018) Vol. 71(1), Page
The Egyptian Journal of Hospital Medicine (April 2018) Vol. 71(1), Page 2315-2321 Role of MRI in Assessment of Hepatocellular Carcinoma (HCC) after TACE (Trans-arterial Chemoembolization) with Persistent
More informationSurgical resection for hepatocellular carcinoma (HCC)
Surgical resection for hepatocellular carcinoma (HCC) Wojciech G Polak, MD, PhD, FEBS Department of Surgery, Division of HPB and Transplant Surgery, Erasmus MC, University Medical Center Rotterdam the
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationEvaluation on liver fibrosis stages using the k-means clustering algorithm
Annals of University of Craiova, Math. Comp. Sci. Ser. Volume 36(2), 2009, Pages 19 24 ISSN: 1223-6934 Evaluation on liver fibrosis stages using the k-means clustering algorithm Marina Gorunescu, Florin
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationCompute-aided Differentiation of Focal Liver Disease in MR Imaging
1063 Compute-aided Differentiation of Focal Liver Disease in MR Imaging Xuejun Zhang a, Masayuki Kanematsu b, Hiroshi Fujita c, Takeshi Hara c, Hiroshi Kondo b, Xiangrong Zhou c, Wenguang Li a and Hiroaki
More informationAssessment of Liver Function: Implications for HCC Treatment
Assessment of Liver Function: Implications for HCC Treatment A/P Dan Yock Young MBBS, PhD, MRCP, MMed. FAMS Chair, University Medicine Cluster. NUHS Head, Department of Medicine, National University of
More informationPediatric Liver Tumors and Transplantation. Northwest Regional Pediatric Live Disease Symposium, Seattle WA, April 12, 2008
Pediatric Liver Tumors and Transplantation Northwest Regional Pediatric Live Disease Symposium, Seattle WA, April 12, 2008 Liver transplantation for primary liver tumours in children WHEN? - patient selection
More informationAASLD Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital
AASLD 2017 - Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital THE CHANGING LANDSCAPE IN THE TREATMENT OF HCC DISCLAIMER Please note:
More informationin Hepatocellular Carcinoma
in Hepatocellular Carcinoma The following summarises the key data supporting the use of SIR-Spheres Y-90 resin microspheres in the treatment of primary liver cancer due to hepatocellular carcinoma (HCC):
More informationTranscatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies
Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies Policy Number: 8.01.11 Last Review: 6/2018 Origination: 8/2005 Next Review: 6/2019 Policy Blue Cross and Blue
More informationONCOLOGY LETTERS 15: , 2018
ONCOLOGY LETTERS 15: 855-862, 2018 Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans arterial chemoembolization therapy ZHAN
More informationHepatocellular Carcinoma (HCC): Burden of Disease
Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and
More informationIl treatment plan nella terapia sistemica dell epatocarcinoma
Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione
More informationAspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis
The Turkish Journal of Pediatrics 2015; 57: 492-497 Original Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis Aysel Ünlüsoy-Aksu 1,
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationMulticenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma
pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 214;46(4):348-357 Original Article http://dx.doi.org/.4143/crt.213.142 Open Access Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor
More information